Image

HCMR Re-Imaging Study

HCMR Re-Imaging Study

Recruiting
18-65 years
All
Phase N/A

Powered by AI

Overview

This study aims to learn what might predict heart problems (like sudden death from a fast heart rhythm or heart failure) in people with a genetic condition called hypertrophic cardiomyopathy (HCM). HCM causes the heart muscle to become thick, which can make the heart stiff and harder to work properly. It can also affect the heart's electrical system.

This study is looking to enroll patients that were previously part of a research project called "HCMR - Novel Predictors of Outcome in Hypertrophic Cardiomyopathy." The results of that study are still being reviewed, but they might show that people who had a substance called Gadolinium (MRI contrast or dye) collected in their heart muscle may have a higher risk for heart problems, including sudden cardiac death. This is called "late gadolinium enhancement" (LGE). This study is aiming to do follow-up imaging on those patients to better understand how LGE affects people with HCM.

Eligibility

Inclusion Criteria:

Patients in the original HCMR cohort with:

  1. Obstructive HCM
    • Males and females between 18 and 65 years of age
    • BMI \< 35 kg/m2
    • LVOT-G at entry as follows:

Resting gradient ≥50 mmHg OR Resting gradient ≥30 mmHg and \<50 mmHg with post-Valsalva LVOT-G ≥50 mmHg

• NYHA Class II or III or
2. Non-obstructive HCM

  • Same criteria as above except resting LVOT-G is \<30mmHg and post-Valsalva gradient \<50mm Hg
  • BMI \<40kg/m2
  • Elevated NT-proBNP \> 300 pg/mL at the time of enrollment
  • LVEF ≥55%

Exclusion Criteria:

  • Paroxysmal atrial fibrillation or flutter documented prior to entry.
  • Paroxysmal or permanent atrial fibrillation requiring rhythm restoring treatment (eg, direct-current cardioversion, ablation procedure, or antiarrhythmic therapy) ≤6 months prior to entry. (This exclusion does not apply if atrial fibrillation has been treated with anticoagulation and adequately rate-controlled for \>6 months.)
  • History of syncope or sustained ventricular tachyarrhythmia with exercise within 6 months prior to entry.
  • Pregnancy due to potential risk of gadolinium to the fetus
  • Patients with a pacemaker that are pacer-dependent as they cannot undergo MRI

Study details
    Hypertrophic Cardiomyopathy (HCM)

NCT07054073

Christopher Kramer

13 May 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.